3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Acquired Immunodeficiency Syndrome
1
Interventions
Exercise
19
Drug Therapy
18
pembrolizumab
13
Capecitabine
11
Blood Specimen Collection
11
Surveys and Questionnaires
10
Radiotherapy
10
Paclitaxel
9
Dexamethasone
9
Nivolumab
8
Standard of Care
7
Oxaliplatin
7
Fluorouracil
7
Erlotinib Hydrochloride
7
apatinib
6
Interviews as Topic
6
Gemcitabine
6
Control Groups
6
Cisplatin
6
Therapeutics
5
Neoadjuvant Therapy
5
Mindfulness-Based Cognitive Therapy
5
Metformin
5
Injections
5
Everolimus
5
Docetaxel
5
Cyclophosphamide
5
Bevacizumab
5
sintilimab
4
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasms
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled